Skip to main content

Xerosis

1
Pipeline Programs
2
Companies
4
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
1
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Nordic Pharma
Nordic PharmaFrance - Paris
1 program
1
SQINPhase 2/31 trial
Active Trials
NCT02429206Completed10Est. Jun 2015
Pierre Fabre
Pierre FabreFrance - Aignan
1 program
Cosmetic productN/A3 trials
Active Trials
NCT07577921Completed80Est. Apr 2026
NCT07576023Completed90Est. Jun 2025
NCT04181177Completed29Est. Mar 2022

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Nordic PharmaSQIN
Pierre FabreCosmetic product
Pierre FabreCosmetic product
Pierre FabreCosmetic product

Clinical Trials (4)

Total enrollment: 209 patients across 4 trials

Safety and Efficacy of SQIN™ on Xerosis in Adults With Mobility Problems and Paralysis

Start: Apr 2015Est. completion: Jun 201510 patients
Phase 2/3Completed
NCT07577921Pierre FabreCosmetic product

Evaluation of the Efficacy of a Cosmetic Care in Subjects With Moderate to Severe Atopic Dermatitis, Treated by Systemic Treatments

Start: May 2025Est. completion: Apr 202680 patients
N/ACompleted
NCT07576023Pierre FabreCosmetic product

A 4-weeks Comparative Study of Cosmetic Product Versus Standard Medical Care in Subjects With Seborrheic Dermatitis

Start: Feb 2025Est. completion: Jun 202590 patients
N/ACompleted
NCT04181177Pierre FabreCosmetic product

Efficacy Study of Cosmetic Product on Xerosis Induced by Systemic Anticancer Treatments

Start: Feb 2019Est. completion: Mar 202229 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.